JUN 13, 2017 06:16 PM PDT

A Novel Drug for Slowing the Progression of Heart Valve Disease

WRITTEN BY: Kara Marker

A monoclonal antibody-based drug called SYN0012 is currently being investigated in human clinical trials for the treatment of rheumatoid arthritis, an autoimmune disease. However, the anti-inflammatory activity of this drug may also lead to it being a treatment for aortic valve stenosis, the first of its kind.

Credit: Lee Health

Aortic valve stenosis is a disease of the heart valve that allow blood to pass through to the body’s vessels for delivering oxygen and nutrients to tissues. This disease is characterized by valve calcification, or hardening, from excess fibroblast-produced cadherin-11, a binding protein. Abnormally high levels of cadherin-11 leads to stiffening of the heart valve, causing the heart to work harder to pump the same amount of blood to the vessels. Making the heart work too hard can lead to heart failure, and as soon as symptoms begin, heart failure and death become risks.

Now, Vanderbilt University scientists are interested in SYN0012 as a technique to maintain a normal, healthy level of fibroblasts and cadherin-11. The antibody works by binding cadherin-11, a protein which in normal contexts promotes healthy wound healing.

"We believe there is potential for using this drug at the first sign of valve disease to prevent the progression,” said associate professor W. David Merryman from Vanderbilt. “You likely cannot reverse the damage, but we believe the drug can prevent it."

The current treatment approach for aortic valve stenosis is surgical replacement, a dangerous option, especially for older patients. SYN0012 could provide an alternative solution.

How did scientists realize that an anti-inflammatory drug for treating rheumatoid arthritis would work similarly in the context of heart valve calcification? A 2013 Vanderbilt study of heart valve cellular responses, focusing on one specific chemical compound, resulted in two different outcomes.

One graduate student on the project identified the compound as exacerbating valve disease, and the other saw the compound as preventing disease. This anomale led to the discovery of cadherin-11 production and its influence on the progression of valve disease. In further studies, heart valves from patients who had underwent a surgical procedure to replace their valves due to disease had nearly 50 times greater cadherin-11 levels than healthy valves.

"The exciting thing about this drug's potential is that it could allow us to consider a strategy of prevention, as we do with other forms of heart disease, like lowering cholesterol or using ACE inhibitors, explained Vanderbilt cardiologist Mike Baker. “We don't have any interventions for aortic valve stenosis that slow its progression."

The present study was published in the journal Circulation.

Source: Vanderbilt University

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
OCT 13, 2019
Cancer
OCT 13, 2019
Using VR to Design Medicine
Being able to visualize and precisely understand molecular shapes is a key factor in drug design. Over the years, to envision and better understand molecul...
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
Can Ecstasy Treat PTSD and Depression?
Ecstasy, also known as MDMA or “molly”, is a well-known substance known to induce feelings of euphoria and bliss, followed by a notorious, depr...
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
Can Psychedelics Treat Alcoholism?
Some of the first research on psychedelics in clinical settings was to assess their efficacy in treating alcoholism. In fact, LSD-based treatments for the ...
OCT 13, 2019
Microbiology
OCT 13, 2019
The Long Evolutionary History of Antibiotics and Resistance
The world is full of bacteria that have to share the world with myriad species, and often have to live in competition with other microbes....
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
Comparison of Three Frontline Breast Cancer Drugs
Breast cancer affects 250,000 women in the U.S. annually. Those with most common form test positive for hormone receptors (HR+) and negative for the HER2 r...
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
New Potential Early Stage Treatment for Parkinson's
Parkinson’s Disease is the second most common neurodegenerative condition, affecting 35 million people globally. Currently without a cure, researcher...
Loading Comments...